Ovide

Malathion

Taro Pharmaceuticals U.s.a., Inc.
Human Prescription Drug
NDC 51672-5293

Ovide also known as Malathion is a human prescription drug labeled by 'Taro Pharmaceuticals U.s.a., Inc.'. National Drug Code (NDC) number for Ovide is 51672-5293. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Ovide drug includes Malathion - .0005 g/mL . The currest status of Ovide drug is Active.

Drug Information:

Drug NDC:	51672-5293
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name:	Ovide
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type:	Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name:	Malathion
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name:	Taro Pharmaceuticals U.s.a., Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form:	Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status:	Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:	MALATHION - .0005 g/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:	TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Marketing Category:	ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date:	31 Jan, 2014
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date:	01 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number:	ANDA091559
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date:	31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Manufacturer Name:	Taro Pharmaceuticals U.S.A., Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:	Yes
Whether or not the drug has been repackaged for distribution.
NUI:	N0000175723 N0000000177
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:	U5N7SU872W
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:	Cholinesterase Inhibitors [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:	Cholinesterase Inhibitor [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class:	Cholinesterase Inhibitor [EPC] Cholinesterase Inhibitors [MoA]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDC	Description	Marketing Start Date	Marketing End Date	Sample Available
51672-5293-4	1 BOTTLE in 1 CARTON (51672-5293-4) / 59 mL in 1 BOTTLE	31 Jan, 2014	N/A	No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Other medicines with the same generic name

Ovide

Product Elements:

Ovide malathion malathion malathion isopropyl alcohol terpineol limonene, (+/-)- pine needle oil (pinus sylvestris)

Indications and Usage:

Indications and usage ovide lotion is indicated for patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair.

Warnings:

Warnings ovide lotion is flammable. the lotion and wet hair should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. do not smoke while applying lotion or while hair is wet. allow hair to dry naturally and to remain uncovered after application of ovide lotion. ovide lotion should only be used on children under the direct supervision of an adult. if ovide lotion comes into contact with the eyes, flush immediately with water. consult a physician if eye irritation persists. if skin irritation occurs, discontinue use of product until irritation clears. reapply the ovide lotion, and if irritation reoccurs, consult a physician. chemical burns including second-degree burns and stinging sensations may occur with the use of ovide lotion. general keep out of reach of children. close eyes tightly during product application. if accidentally placed in the eye, flush immediately with water. use only on scalp hair. information to patients ovide lotion Read more...

is flammable. the lotion and hair wet with lotion should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. do not smoke while applying lotion or while hair is wet. the person applying ovide lotion should wash hands after application. allow hair to dry naturally and to remain uncovered after application of ovide lotion. ovide lotion should only be used on children under the direct supervision of an adult. children should be warned to stay away from lighted cigarettes, open flames, and electric heat sources while the hair is wet. in case of accidental ingestion of ovide lotion by mouth, seek medical attention immediately. if you are pregnant or nursing, you should contact your physician before using ovide lotion. if ovide lotion comes into contact with the eyes, flush immediately with water. consult a physician if eye irritation persists or if visual changes occur. if skin irritation occurs, wash scalp and hair immediately. if the irritation clears, ovide lotion may be reapplied. if irritation reoccurs, consult a physician. burns and stinging sensations may occur when using ovide lotion. apply ovide lotion on the scalp hair in an amount just sufficient to thoroughly wet hair and scalp. pay particular attention to the back of the head and neck when applying ovide lotion. anyone applying ovide lotion should wash hands immediately after the application process is complete. allow hair to dry naturally and to remain uncovered. shampoo hair after 8 to 12 hours, again paying attention to the back of the head and neck while shampooing. rinse hair and use a fine - toothed (nit) comb to remove dead lice and eggs. if lice are still present after 7 - 9 days, repeat with a second application of ovide lotion. further treatment is generally not necessary. other family members should be evaluated by a physician to determine if infested, and if so, receive treatment. laboratory tests there are no special laboratory tests needed in order to use this medication. carcinogenesis , mutagenesis, and impairment of fertility carcinogenesis, mutagenesis and impairment of fertility have not been studied with ovide lotion (0.5% pharmaceutical grade malathion). however, following long-term oral administration of technical grade malathion to rodents via dietary supplementation, increased incidences of hepatocellular neoplastic lesions were observed in b6c3f1 mice dosed for 18 months at malathion doses greater than 1500 mg/kg/day, and in female f344 rats dosed for 2 years at malathion doses greater than 400 mg/kg/day. these tumors occurred only in association with severe hepatic toxicity and chronic suppression of acetylcholinesterase activity, or at doses causing excessive mortality. based on body surface area, doses at which carcinogenic effects were observed in rodents following life-time exposures to malathion were approximately 14- to 26-fold greater than the maximum dose anticipated in a 10 kg child following a single use of ovide lotion, assuming 100% bioavailability. actual systemic exposures are expected to be less than 10% of the administered dose. the malathion of greater than pharmaceutical-grade purity used in ovide lotion has not been tested for genotoxicity. the technical-grade malathion (95% pure) was found to be negative in salmonella typhimurium , equivocally positive in the mouse lymphoma cell assay, and positive in in vitro chromosomal aberration and sister chromatid exchange assays. fifteen separate in vitro gene mutation studies with malathion of unknown purity have reported negative results, while three studies reported malathion to be mutagenic in bacterial cells. both technical grade (94â96.5%) and purified (98-99%) malathion have been reported to cause chromosomal aberrations and sister chromatid exchanges in vitro in human and hamster cell lines. in vivo chromosomal aberration and micronucleus studies of technical- grade malathion are reported to be positive, whereas an in vivo chromosomal aberration study of >99% pure malathion was reported to be negative. furthermore, mice exposed to malathion in their drinking water for 7 weeks demonstrated no evidence of chromosome damage in bone marrow cells, spermatogonia, or primary spermatocytes. lack of details makes independent evaluation of the results of these assays impossible. ashby and purchase have suggested that impurities may be responsible for some of the observed genetic activity of malathion. reproduction studies performed with malathion in rats at doses over 180 fold greater than those anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability) revealed no evidence of impaired fertility. pregnancy pregnancy category b there was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. a study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during a three - generation evaluation period. these doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability). because animal reproduction studies are not always predictive of human responses, this drug should be used (or handled) during pregnancy only if clearly needed. nursing mothers malathion in an acetone vehicle has been reported to be absorbed through human skin to the extent of 8% of the applied dose. however, percutaneous absorption from the ovide Â® (malathion) lotion, 0.5% formulation has not been studied, and it is not known whether malathion is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when ovide lotion is administered to (or handled by) a nursing mother. pediatric use the safety and effectiveness of ovide lotion in children less than 6 years of age has not been established via well-controlled trials.

General Precautions:

General keep out of reach of children. close eyes tightly during product application. if accidentally placed in the eye, flush immediately with water. use only on scalp hair.

Dosage and Administration:

Dosage and administration apply ovide lotion on dry hair in amount just sufficient to thoroughly wet the hair and scalp. pay particular attention to the back of the head and neck while applying ovide lotion. wash hands after applying to scalp. allow hair to dry naturally - use no electric heat source, and allow hair to remain uncovered. after 8 to 12 hours, the hair should be shampooed. rinse and use a fine - toothed (nit) comb to remove dead lice and eggs. if lice are still present after 7 - 9 days, repeat with a second application of ovide lotion. further treatment is generally not necessary. other family members should be evaluated by a physician to determine if infested, and if so, receive treatment.

Contraindications:

Contraindications ovide lotion is contraindicated for neonates and infants because their scalps are more permeable and may have increased absorption of malathion. ovide lotion should also not be used on individuals known to be sensitive to malathion or any of the ingredients in the vehicle.

Adverse Reactions:

Adverse reactions malathion has been shown to be irritating to the skin and scalp. other adverse reactions reported are chemical burns including second-degree burns. accidental contact with the eyes can result in mild conjunctivitis. it is not known if ovide lotion has the potential to cause contact allergic sensitization.

Use in Pregnancy:

Pregnancy pregnancy category b there was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. a study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during a three - generation evaluation period. these doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability). because animal reproduction studies are not always predictive of human responses, this drug should be used (or handled) during pregnancy only if clearly needed.

Pediatric Use:

Pediatric use the safety and effectiveness of ovide lotion in children less than 6 years of age has not been established via well-controlled trials.

Overdosage:

Overdosage consideration should be given, as part of the treatment program, to the high concentration of isopropyl alcohol in the vehicle. malathion, although a weaker cholinesterase inhibitor than some other organophosphates, may be expected to exhibit the same symptoms of cholinesterase depletion after accidental ingestion orally. if accidentally swallowed, vomiting should be induced promptly or the stomach lavaged with 5% sodium bicarbonate solution. severe respiratory distress is the major and most serious symptom of organophosphate poisoning requiring artificial respiration, and atropine may be needed to counteract the symptoms of cholinesterase depletion. repeat analyses of serum and rbc cholinesterase may assist in establishing the diagnosis and formulating a long - range prognosis.

Description:

Description ovide lotion contains 0.005 g of malathion per ml in a vehicle of isopropyl alcohol (78%), terpineol, dipentene, and pine needle oil. the chemical name of malathion is (Â±) - [(dimethoxyphosphinothioyl) - thio] butanedioic acid diethyl ester. malathion has a molecular weight of 330.36, represented by c 10 h 19 o 6 ps 2 , and has the following chemical structure: chemical structure

Clinical Pharmacology:

Clinical pharmacology malathion is an organophosphate agent which acts as a pediculicide by inhibiting cholinesterase activity in vivo. inadvertent transdermal absorption of malathion has occurred from its agricultural use. in such cases, acute toxicity was manifested by excessive cholinergic activity, i.e., increased sweating, salivary and gastric secretion, gastrointestinal and uterine motility, and bradycardia (see overdosage ). because the potential for transdermal absorption of malathion from ovide lotion is not known at this time, strict adherence to the dosing instructions regarding its use in children, method of application, duration of exposure, and frequency of application is required.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis , mutagenesis, and impairment of fertility carcinogenesis, mutagenesis and impairment of fertility have not been studied with ovide lotion (0.5% pharmaceutical grade malathion). however, following long-term oral administration of technical grade malathion to rodents via dietary supplementation, increased incidences of hepatocellular neoplastic lesions were observed in b6c3f1 mice dosed for 18 months at malathion doses greater than 1500 mg/kg/day, and in female f344 rats dosed for 2 years at malathion doses greater than 400 mg/kg/day. these tumors occurred only in association with severe hepatic toxicity and chronic suppression of acetylcholinesterase activity, or at doses causing excessive mortality. based on body surface area, doses at which carcinogenic effects were observed in rodents following life-time exposures to malathion were approximately 14- to 26-fold greater than the maximum dose anticipated in a 10 kg child following a single use of ovide lotion, assuming 1 Read more...

00% bioavailability. actual systemic exposures are expected to be less than 10% of the administered dose. the malathion of greater than pharmaceutical-grade purity used in ovide lotion has not been tested for genotoxicity. the technical-grade malathion (95% pure) was found to be negative in salmonella typhimurium , equivocally positive in the mouse lymphoma cell assay, and positive in in vitro chromosomal aberration and sister chromatid exchange assays. fifteen separate in vitro gene mutation studies with malathion of unknown purity have reported negative results, while three studies reported malathion to be mutagenic in bacterial cells. both technical grade (94â96.5%) and purified (98-99%) malathion have been reported to cause chromosomal aberrations and sister chromatid exchanges in vitro in human and hamster cell lines. in vivo chromosomal aberration and micronucleus studies of technical- grade malathion are reported to be positive, whereas an in vivo chromosomal aberration study of >99% pure malathion was reported to be negative. furthermore, mice exposed to malathion in their drinking water for 7 weeks demonstrated no evidence of chromosome damage in bone marrow cells, spermatogonia, or primary spermatocytes. lack of details makes independent evaluation of the results of these assays impossible. ashby and purchase have suggested that impurities may be responsible for some of the observed genetic activity of malathion. reproduction studies performed with malathion in rats at doses over 180 fold greater than those anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability) revealed no evidence of impaired fertility.

Clinical Studies:

Clinical studies two controlled clinical trials evaluated the pediculicidal activity of ovide lotion. patients applied the lotion to the hair and scalp in quantities, up to a maximum of 2 fl. oz., sufficient to thoroughly wet the hair and scalp. the lotion was allowed to air dry and was shampooed with prell shampoo 8 to 12 hours after application. patients in both the ovide lotion group and in the vehicle group were examined immediately after shampooing, 24 hours after, and 7 days after for the presence of live lice. results are shown in the following table: number of patients without live scalp lice treatment immediately after 24 hrs. after 7 days after ovide lotion 129/129 122/129 114/126 ovide vehicle 105/105 63/105 31/105 the presence or absence of ova at day 7 was not evaluated in these studies. the presence or absence of live lice or ova at 14 days following treatment was not evaluated in these studies. the residual amount of malathion on hair and scalp is unknown.

How Supplied:

How supplied ovide Â® (malathion) lotion, 0.5%, is supplied in bottles of 2 fl. oz. (59 ml) ndc 51672-5293-4. stored at 20Â° to 25Â°c (68Â° to 77Â°f) [see usp controlled room temperature] flammable. keep away from heat and open flame.

Information for Patients:

Information to patients ovide lotion is flammable. the lotion and hair wet with lotion should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. do not smoke while applying lotion or while hair is wet. the person applying ovide lotion should wash hands after application. allow hair to dry naturally and to remain uncovered after application of ovide lotion. ovide lotion should only be used on children under the direct supervision of an adult. children should be warned to stay away from lighted cigarettes, open flames, and electric heat sources while the hair is wet. in case of accidental ingestion of ovide lotion by mouth, seek medical attention immediately. if you are pregnant or nursing, you should contact your physician before using ovide lotion. if ovide lotion comes into contact with the eyes, flush immediately with water. consult a physician if eye irritation persists or if visual changes occur. if skin irritation occurs, wash scalp Read more...

and hair immediately. if the irritation clears, ovide lotion may be reapplied. if irritation reoccurs, consult a physician. burns and stinging sensations may occur when using ovide lotion. apply ovide lotion on the scalp hair in an amount just sufficient to thoroughly wet hair and scalp. pay particular attention to the back of the head and neck when applying ovide lotion. anyone applying ovide lotion should wash hands immediately after the application process is complete. allow hair to dry naturally and to remain uncovered. shampoo hair after 8 to 12 hours, again paying attention to the back of the head and neck while shampooing. rinse hair and use a fine - toothed (nit) comb to remove dead lice and eggs. if lice are still present after 7 - 9 days, repeat with a second application of ovide lotion. further treatment is generally not necessary. other family members should be evaluated by a physician to determine if infested, and if so, receive treatment.

Package Label Principal Display Panel:

Principal display panel - 59 ml bottle carton ndc 51672-5293-4 ovide Â® (malathion) lotion, 0.5% in isopropyl alcohol (78%), terpineol, dipentene and pine needle oil. pediculicide/ovicide warning: contains flammable alcohol. avoid smoking, open flame and hair dryers. allow hair to dry naturally and uncovered. rx only taro pharma Â® 2 fl. oz. (59 ml) principal display panel - 59 ml bottle carton

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.